The effect of Cichorium intybus on non alcholic fatty liver disease

Effects of Hydroalcoholic extract of Cichorium intybus leaves on liver functional indexes in patient with Non Alcholic Fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190415043279N2

Enrollment

Registered

2020-01-02

Start date

2020-01-05

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcholic Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Capsule containing hydroalcoholic extract of Cichorium intybus leaves at a dose of 500 mg per day for two consecutive months. These iral capsules of Cichorium inty

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with aminotransferases greater than 1.5 times the normal maximum Ultrasound images with Stage 2, 3

Exclusion criteria

Exclusion criteria: Alcohol consumption (more than 140 cc in men and 70 cc in women per week) Patients with viral hepatitis Diabetic patients Patients taking lipid-lowering drugs Pregnancy and lactation Patients taking drugs that affect the liver enzymes Patients with autoimmune diseases People with a history of bleeding and hemostatic disorders Patients taking anticoagulants like warfarin Patients with allergies to herbs and herbal remedies

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase (ALT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Aspartate Aminotransferase (AST). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Grade of fatty liver. Timepoint: At baseline and end of the study. Method of measurement: Sonography.;Alkaline Phosphatase (ALP). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Bilirubin. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Cholestrol. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Triglyceride. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;High Density Lipoprotein (HDL). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Low Density Lipoprotein (LDL). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Fasting Blood Sugar (FBS). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Body Mass Index (BMI). Timepoint: At baseline and end of the study. Method of measurement: by measuring height and weight using a scale and height meter.	—

Measure

Time frame

Alanine Aminotransferase (ALT). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Aspartate Aminotransferase (AST). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Grade of fatty liver. Timepoint: At baseline and end of the study. Method of measurement: Sonography.;Alkaline Phosphatase (ALP). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Bilirubin. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Cholestrol. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Triglyceride. Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;High Density Lipoprotein (HDL). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Low Density Lipoprotein (LDL). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Fasting Blood Sugar (FBS). Timepoint: At baseline and end of the study. Method of measurement: Using biochemical method and Pars azmoon Company's Kit.;Body Mass Index (BMI). Timepoint: At baseline and end of the study. Method of measurement: by measuring height and weight using a scale and height meter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahid Yousefinejad

Sanandaj University of Medical Sciences

hooman56y@yahoo.com+98 87 3366 4645

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026